1、Qi WX, Shen Z, Yang Yao#. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.. Cancer Chemother Pharmacol,2012;69(1):99-106
2、Qi WX, Tang LN, He AN, Shen Z, Yao Y.#. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: A meta-analysis of four phase III trials.. Breast,2012;2012:1-6
3、Yao Y#, Fang ZP, Chen H, Yue L, Min DL, Tang LN, Yu WX, Kung HF, Lin MC, Shen Z.. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.. Cancer Gene Ther.,2012;19(9):601-8
4、Qi WX, Tang LN, He AN, Shen Z, Lin F, Yang Yao（通讯作者）#. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison. Curr Med Res Opin,2012;28(4):643-650
5、Qi WX, He AN, Tang LN, Shen Z, Lin F, Yang Yao（通讯作者）#. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. The Tohoku Jpn J Clin Oncol,2012;42(5):427-431
6、Qi WX, Tang LN, He AN, Shen Z, Yao Y#. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol,2012;138(5):745-751
7、Qi Wei-Xiang, Shen Zan , Lin Feng， Yang Yao（通讯作者）. Incidence and Risk of Hypertension with Vandetanib in Cancer Patients: A Systematic review and Meta-analysis of 11 clinical trials. J Cancer Res Clin Oncol,2012;
8、Hongtao L, Hui Z, Bingshun W, Xiaojin W, Zhiyu W, Shuier Z, Aina H, Yuanjue S, Daliu M, Zan S, Yang Y.#. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: A meta-analysis.. Surgical Oncology,2012;21(4):165-170
9、乔光磊, 祁伟祥, 郑水儿, 闵大六, 沈赞,姚阳#. 骨肉瘤误诊误治30例的临床特征及预后分析. 肿瘤,2012;32:622-627
10、闵大六, 沈赞, 林峰, 徐晓丽, 黄文涛, 姚阳#. Runx2和Ezrin基因在骨肉瘤组织中的表达及其临床意义. 中国癌症杂志,2012;22:685-689
11、赵晖, 王智煜, 杨玉妹, 郑研, 宁琳琳, 李洪涛 ,姚阳#. 骨代谢标志物CTx、OST、BAP和PINP在乳腺癌骨转移患者血清中的变化. 中国癌症杂志,2012;22:469-480
12、汤丽娜, 林峰, 沈赞, 孙元珏, 姚阳#. 异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤的Ⅲ期临床试验. 肿瘤,2012;32:38-743
13、Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y.#. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.. Lung,2012;190(5):477-85
14、Qi WX, He AN, Tang LN, Shen Z, Yang Yao#. Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.. Med Oncol,2012;29(3):2229-33
15、Aina He, Weixiang Qi, Yujing Huang, Tao Feng, Jie Chen#, Yuanjue Sun, Zan Shen and Yang Yao. CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study.. EXPERIMENTAL AND THERAPEUTIC MEDICINE,2012;4:435-441
16、Qi Wei-Xiang, Shen Zan , Lin Feng, Sun Yuan-jue, Min Da-liu, Tang Li-Na, He Ai-Na, Yang Yao#. Incidence and Risk of Hypertension with Vandetanib in Cancer Patients: A Systematic review and Meta-analysis of 11 clinical trials.. British journal of clinical pharmacology,2012;2012:4-10
17、Aina He, Weixiang Qi, Yujing Huang, Yuanjue Sun, Zan Shen, Hui Zhao,Yumei Yang, Yang Yao#. Comparison of pirarubicin-based versus gemcitabine–docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.. Int J Clin Oncol.,2012;2012:4-26
18、Zheng SE, Xiong S, Lin F, Qiao GL, Feng T, Shen Z, Min DL, Zhang CL, Yao Y#. Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.. Acta Pharmacol Sin.,2012;33(6):832-8
19、黄毓婧, 何爱娜, 孙元珏, 沈赞, 姚阳#. CD133 骨肉瘤细胞的获取及其干细胞特性的初步鉴定. 肿瘤,2012;22(10):767-772
20、K. Han, Y. Sun, J. Zhang, A. He, S. Zheng, Z. Shen, Y. Yao#. Cyclophosphamide-hydroxycamptothecin as second-line chemotherapy for advanced Ewing's sarcoma: Experience of a single institution. Asia Pac J Clin Oncol,2012;11(26):12018-12018
21、杜雪菲, 丰涛, 何爱娜, 刘增军, 汤丽娜, 沈赞, 姚阳#. Med19基因表达变化在骨肉瘤Saos2细胞增殖中的功能研究. 中国癌症杂志,2011;21(6):435-440
22、祁伟祥, 何爱娜, 汤丽娜, 沈赞, 姚阳#. 成人骨肉瘤52例预后因素的COX比例风险模型分析. 肿瘤,2011;31(9):846-850
23、刘增军, 沈赞, 赵晖, 杜雪菲, 丰涛, 李洪涛, 林李家宓, 姚阳#. 腺相关病毒介导的肝细胞生长因子Kringle1结构域对人前列腺癌裸鼠骨移植瘤生长的影响. 肿瘤,2011;31(7):585-590
24、吴福红,姚阳#. EphA2蛋白表达与结直肠癌浸润性及微血管生成的关系. 现代肿瘤医学,2011;19:2268-2271
25、祁伟祥, 何爱娜, 汤丽娜, 沈赞,姚阳#. 儿童骨肉瘤与青年骨肉瘤临床特点比较及预后影响因素分析. 中国肿瘤临床,2011;38(21):1330-1334
26、Qi WX, Tang LN, He AN, Shen Z, Yang Yao#. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.. Lung,2011;189(6):437-443
27、Qi WX, Shen Z, Yang Yao. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. . J Cancer Res Clin Oncol,2011;137(12):1785-1790
28、H. Zhao, K. L. Han, Z. Y. Wang, Y. Chen, H. T. Li, J. L. Zeng, Z. Shen and Y. Yao. Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.. Med Sci Monit,2011;17(11):626-633
29、 H. Zhao, Y. Yao#, Z. Wang, F. Lin, Y. Sun and P. Chen. Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. J Chemother.,2011;22(2):119-24
30、赵晖, 杨晨, 王智煜, 姚阳#. 含吡柔比星方案治疗骨肉瘤肺转移患者的疗效及心脏功能评估. 肿瘤,2010;30(10):860-864
31、王智煜, 杨晨, 高云潮, 沈赞, 杨玉妹, 赵晖 , 姚阳#. 骨转换标志物在非小细胞肺癌骨转移临床应用中价值的研究. 中国癌症杂志,2010;20(3):202-206
32、孙元珏, 张剑军, 汤丽娜, 郑水儿, 王智昱, 赵晖, 林峰, 沈赞, 姚阳#. 137例MAID方案一线化疗转移软组织肉瘤的回顾性临床分析. 中国肿瘤临床,2010;37(24):1411-1414
33、卞晓洁, 陈平, 杨晨, 王智煜, 李洪涛, 沈赞, 姚阳, 赵晖#. 血清MMP-9和ICAM-1水平对非小细胞肺癌骨转移诊断和预后的意义. 临床肿瘤学杂志,2010;15(8):680-684
34、Yao Yang（姚阳，第一作者、通讯作者）*, Dong Yang，Feng Lin, Hui Zhao et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncology Reports, 2009; 21(1); 229-235
35、Yao Yang（姚阳，第一作者、通讯作者）*, et al. Combimed chemotherapy of hydroxycamptothecine with oxaliptantin as an adjuvant treatment for human colorectal cancer. The Tohoku Journal of Experiment Medicine,2008;215(3): 267-278
36、Yao Yang（姚阳，第一作者、通讯作者）*, et al.. The expression of CRM1 is Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5- fluorouracil and leucovorin in treatment of advanced colorectal cancer. . Chinese medical journal,2006;119(21):1829-1833
|
